KDR and gastric cancer: Therefore, the targeted drugs that are useful in the treatment of other tumours are not effective in GC therapy, and despite the development of novel drugs for GC, trastuzumab and ramucirumab (targeting HER2 and VEGFR2, respectively) are the only targeted therapies approved to date5.